Press Releases

News

Opioid Prescriptions Can Be Drastically Reduced After Surgery with No Increase in Pain, Study Shows

Pain after surgery can be effectively managed with minimal or no opioids, according to research conducted at Roswell Park Comprehensive Cancer Center and published today in JAMA Network Open. A two-year study by a multidisciplinary team of surgeons and other cancer specialists shows that the amount of opioid medications prescribed after surgery can be drastically reduced without negatively affecting pain scores, postoperative complications or patient requests for additional opioids, demonstrating that alternative approaches to pain management can be both safe and highly effective.

News

Join Roswell Park for a Hopeful Tribute to All Affected by Cancer at Tree of Hope 2018

Roswell Park Comprehensive Cancer Center’s 24th annual Tree of Hope lighting ceremony will draw cancer patients, survivors, caregivers and loved ones together for a holiday celebration Friday, Dec. 14, from 4:30 to 6:30 p.m. in Kaminski Park and Gardens on the Roswell Park campus. This free, family-friendly holiday celebration will be held in honor of all who are touched by cancer. It will include live music, carriage rides, visits with Santa and Mrs. Claus, face painting and a gingerbread house raffle.
News

Roswell Park’s Dr. Igor Puzanov Honored for His Many Contributions to Melanoma Research

Roswell Park Comprehensive Center’s Igor Puzanov, MD, MSci, FACP, was honored for his “outstanding and lifelong contributions to melanoma research” during the just-concluded Melanoma and Immunotherapy Bridge research meeting in Naples, Italy. Dr. Puzanov, who is Chief of Melanoma and Director of the Early Phase Clinical Trials Program at Roswell Park, received the award from Italy’s Fondazione Melanoma, or Melanoma Foundation.
News

Roswell Park Hematologists Bring Expertise in Cellular Therapies, Genomic Testing and Rare Lymphoma to ASH 2018

Roswell Park Comprehensive Cancer Center hematology experts from many disciplines and subspecialties were invited to present new research at the American Society of Hematology (ASH) 60th Annual Meeting, which begins today and continues through Tuesday, Dec. 4, in San Diego, California. The dozens of research projects they will highlight include new research on management of aggressive and rare lymphomas, approaches for optimizing cellular therapies such as blood and marrow transplant, and decision-making around genomic testing for patients with acute myeloid leukemia.
News

Brain Cancer Immunotherapy SurVaxM Extends Survival, Even in Hard-to-Treat Patients

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. These new findings — including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT — were presented earlier this month at the Society for Neuro-Oncology (SNO) Annual Meeting in New Orleans.
News

Brain Cancer Immunotherapy SurVaxM Extends Survival, Even in Hard-to-Treat Patients

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. These new findings — including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT — were presented Friday at the Society for Neuro-Oncology (SNO) Annual Meeting in New Orleans.
News

Research Review Underscores Progress in Treating Kidney Cancer, Importance of Close Patient Monitoring

In an effort to compile and summarize the latest knowledge about immunotherapy combinations and their implications, a group of kidney cancer immunotherapy experts led by Saby George, MD, of Roswell Park Comprehensive Cancer Center have written a new research review article assessing current approaches to treating patients newly diagnosed with kidney cancer and also looking ahead to some of the most pressing questions still to be answered related to these emerging therapies. Published by the journal JAMA Oncology, the review article highlights the path to approval for the new standard of care for these patients — ipilimumab, also known as Yervoy, together with nivolumab, also known as Opdivo.
News

Hockey Fights Cancer Night in Buffalo Slated for November 27

The Buffalo Sabres today announced the team, in partnership with Roswell Park Comprehensive Cancer Center, will again take part in the NHL’s Hockey Fights Cancer™ program during the team’s home game against the San Jose Sharks on Tuesday, Nov. 27, at 7 p.m.